A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma

Mutation Research - Reviews in Mutation Research

Volumn 750, Issue 2, 2012, Pages 132-140

  Melaiu, Ombretta ^a   Cristaudo, Alfonso ^a   Melissari, Erika ^a   Di Russo, Manuela ^a   Bonotti, Alessandra ^a   Bruno, Rossella ^a   Foddis, Rudy ^a   Gemignani, Federica ^a   Pellegrini, Silvia ^a   Landi, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Data mining; Gene expression profiling; Malignant pleural mesothelioma; Transcriptome studies

Indexed keywords

ACETYLSALICYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CAVEOLIN 1; CISPLATIN; CYCLIN B1; FIBROBLAST GROWTH FACTOR 2; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR MARKER;

ASS1 GENE; AURKA GENE; BIRC5 GENE; CANCER INHIBITION; CLINICAL TRIAL; CONSENSUS; DATA MINING; DEREGULATION; DOWN REGULATION; EEF2 GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; IFITM1 GENE; JUNB GENE; MCM2 GENE; MICROARRAY ANALYSIS; MICROENVIRONMENT; MK167 GENE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PTGS2 GENE; REPRODUCIBILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SULF1 GENE; TOP2A GENE; TUMOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DATA MINING; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859110059     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2011.12.003     Document Type: Review

References (78)

1. Spirtas R., Heineman E.F., Bernstein L., Beebe G.W., Keehn R.J., Stark A., Harlow B.L., Benichou J. Malignant mesothelioma: attributable risk of asbestos exposure. Occup. Environ. Med. 1994, 51:804-811.
2. Cristaudo A., Foddis R., Vivaldi A., Buselli R., Gattini V., Guglielmi G., Cosentino F., Ottenga F., Ciancia E., Libener R., Filiberti R., Neri M., Betta P., Tognon M., Mutti L., Puntoni R. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res. 2005, 65:3049-3052.
3. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357:444-445.
4. Montanaro F., Rosato R., Gangemi M., Roberti S., Ricceri F., Merler E., Gennaro V., Romanelli A., Chellini E., Pascucci C., Musti M., Nicita C., Barbieri P.G., Marinaccio A., Magnani C., Mirabelli D. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int. J. Cancer 2009, 124:201-207.
5. Armato S.G., Oxnard G.R., MacMahon H., Vogelzang N.J., Kindler H.L., Kocherginsky M., Starkey A. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med. Phys. 2004, 31:1105-1115.
6. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de K.N., Winzell P., Hellstrom K.E., Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
7. Cristaudo A., Foddis R., Vivaldi A., Guglielmi G., Dipalma N., Filiberti R., Neri M., Ceppi M., Paganuzzi M., Ivaldi G.P., Mencoboni M., Canessa P.A., Ambrosino N., Chella A., Mutti L., Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 2007, 13:5076-5081.
8. Grigoriu B.D., Scherpereel A., Devos P., Chahine B., Letourneux M., Lebailly P., Gregoire M., Porte H., Copin M.C., Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13:2928-2935.
9. Chon H.S., Lancaster J.M. Microarray-based gene expression studies in ovarian cancer. Cancer Control 2011, 18:8-15.
10. Godley L.A., Cunningham J., Dolan M.E., Huang R.S., Gurbuxani S., McNerney M.E., Larson R.A., Leong H., Lussier Y., Onel K., Odenike O., Stock W., White K.P., Le Beau M.M. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin. Oncol. 2011, 38:215-224.
11. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
12. Woo H.G., Park E.S., Thorgeirsson S.S., Kim Y.J. Exploring genomic profiles of hepatocellular carcinoma. Mol. Carcinog. 2011, 50:235-243.
13. Zhao Y.L., Piao C.Q., Wu L.J., Suzuki M., Hei T.K. Differentially expressed genes in asbestos-induced tumorigenic human bronchial epithelial cells: implication for mechanism. Carcinogenesis 2000, 21:2005-2010.
14. Sandhu H., Dehnen W., Roller M., Abel J., Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 2000, 21:1023-1029.
15. Rihn B.H., Mohr S., McDowell S.A., Binet S., Loubinoux J., Galateau F., Keith G., Leikauf G.D. Differential gene expression in mesothelioma. FEBS Lett. 2000, 480:95-100.
16. Kettunen E., Nissen A.M., Ollikainen T., Taavitsainen M., Tapper J., Mattson K., Linnainmaa K., Knuutila S., El-Rifai W. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int. J. Cancer 2001, 91:492-496.
17. Gordon G.J., Jensen R.V., Hsiao L.L., Gullans S.R., Blumenstock J.E., Richards W.G., Jaklitsch M.T., Sugarbaker D.J., Bueno R. Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl. Cancer Inst. 2003, 95:598-605.
18. Crispi S., Calogero R.A., Santini M., Mellone P., Vincenzi B., Citro G., Vicidomini G., Fasano S., Meccariello R., Cobellis G., Menegozzo S., Pierantoni R., Facciolo F., Baldi A., Menegozzo M. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009, 4:e7016.
19. Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G., Sugarbaker D.J., Bueno R. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. 2005, 166:1827-1840.
20. Hoang C.D., D'Cunha J., Kratzke M.G., Casmey C.E., Frizelle S.P., Maddaus M.A., Kratzke R.A. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004, 125:1843-1852.
21. Cardillo I., Spugnini E.P., Verdina A., Galati R., Citro G., Baldi A. Cox and mesothelioma: an overview. Histol. Histopathol. 2005, 20:1267-1274.
22. Khan Z., Khan N., Tiwari R.P., Sah N.K., Prasad G.B., Bisen P.S. Biology of Cox-2: an application in cancer therapeutics. Curr. Drug Targets 2011, 12:1082-1093.
23. Harris R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17:55-67.
24. Zaffaroni N., Costa A., Pennati M., De M.C., Affini E., Madeo M., Erdas R., Cabras A., Kusamura S., Baratti D., Deraco M., Daidone M.G. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell. Oncol. 2007, 29:453-466.
25. Sampath J., Pelus L.M. Alternative splice variants of survivin as potential targets in cancer. Curr. Drug Discov. Technol. 2007, 4:174-191.
26. Delage B., Fennell D.A., Nicholson L., McNeish I., Lemoine N.R., Crook T., Szlosarek P.W. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 2010, 126:2762-2772.
27. Ramos-Nino M.E., Timblin C.R., Mossman B.T. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 2002, 62:6065-6069.
28. Sington J.D., Morris L.S., Nicholson A.G., Coleman N. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003, 42:498-502.
29. Crispi S., Fagliarone C., Biroccio A., D'Angelo C., Galati R., Sacchi A., Vincenzi B., Baldi A., Verdina A. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer 2010, 70:271-279.
30. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van M.E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 1999, 189:72-78.
31. Taheri Z.M., Mehrafza M., Mohammadi F., Khoddami M., Bahadori M., Masjedi M.R. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch. Pathol. Lab. Med. 2008, 132:694-697.
32. Amatya V.J., Takeshima Y., Kohno H., Kushitani K., Yamada T., Morimoto C., Inai K. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology 2009, 55:10-19.
33. Lee A.Y., He B., You L., Dadfarmay S., Xu Z., Mazieres J., Mikami I., McCormick F., Jablons D.M. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004, 23:6672-6676.
34. Kohno H., Amatya V.J., Takeshima Y., Kushitani K., Hattori N., Kohno N., Inai K. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol. Rep. 2010, 24:423-431.
35. Romagnoli S., Fasoli E., Vaira V., Falleni M., Pellegrini C., Catania A., Roncalli M., Marchetti A., Santambrogio L., Coggi G., Bosari S. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am. J. Pathol. 2009, 174:762-770.
36. Androic I., Kramer A., Yan R., Rodel F., Gatje R., Kaufmann M., Strebhardt K., Yuan J. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8:391.
37. Dong L., Jensen R.V., De R.A., Gordon G.J., Xu Y., Sugarbaker D.J., Bueno R. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing. BMC Med. Genet. 2009, 10:149.
38. Cristaudo A., Bonotti A., Simonini S., Bruno R., Foddis R. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark. Med. 2011, 5:261-273.
39. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., Aiko S., Yoshizumi Y., Ichikawa D., Otsuji E., Inazawa J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.
40. Zirn B., Hartmann O., Samans B., Krause M., Wittmann S., Mertens F., Graf N., Eilers M., Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int. J. Cancer 2006, 118:1954-1962.
41. Nakamura J., Aoyagi S., Nanchi I., Nakatsuka S., Hirata E., Shibata S., Fukuda M., Yamamoto Y., Fukuda I., Tatsumi N., Ueda T., Fujiki F., Nomura M., Nishida S., Shirakata T., Hosen N., Tsuboi A., Oka Y., Nezu R., Mori M., Doki Y., Aozasa K., Sugiyama H., Oji Y. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int. J. Oncol. 2009, 34:1181-1189.
42. Brase J.C., Schmidt M., Fischbach T., Sultmann H., Bojar H., Koelbl H., Hellwig B., Rahnenfuhrer J., Hengstler J.G., Gehrmann M.C. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin. Cancer Res. 2010, 16:2391-2401.
43. Cole K.A., Huggins J., Laquaglia M., Hulderman C.E., Russell M.R., Bosse K., Diskin S.J., Attiyeh E.F., Sennett R., Norris G., Laudenslager M., Wood A.C., Mayes P.A., Jagannathan J., Winter C., Mosse Y.P., Maris J.M. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3336-3341.
44. Malkas L.H., Herbert B.S., bdel-Aziz W., Dobrolecki L.E., Liu Y., Agarwal B., Hoelz D., Badve S., Schnaper L., Arnold R.J., Mechref Y., Novotny M.V., Loehrer P., Goulet R.J., Hickey R.J. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19472-19477.
45. Melotti A., Daga A., Marubbi D., Zunino A., Mutti L., Corte G. In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer 2010, 10:54.
46. Lee A.Y., He B., You L., Xu Z., Mazieres J., Reguart N., Mikami I., Batra S., Jablons D.M. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem. Biophys. Res. Commun. 2004, 323:1246-1250.
47. Wali A., Morin P.J., Hough C.D., Lonardo F., Seya T., Carbone M., Pass H.I. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 2005, 48:19-29.
48. Falleni M., Pellegrini C., Marchetti A., Roncalli M., Nosotti M., Palleschi A., Santambrogio L., Coggi G., Bosari S. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 2005, 48:211-216.
49. Gordon G.J., Dong L., Yeap B.Y., Richards W.G., Glickman J.N., Edenfield H., Mani M., Colquitt R., Maulik G., Van O.B., Sugarbaker D.J., Bueno R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl. Cancer Inst. 2009, 101:678-686.
50. Illei P.B., Rusch V.W., Zakowski M.F., Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 2003, 9:2108-2113.
51. Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009, 64:140-147.
52. Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 2011, 43:668-672.
53. Wong L., Zhou J., Anderson D., Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136.
54. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005, 49(Suppl. 1):S95-S98.
55. Krasinskas A.M., Bartlett D.L., Cieply K., Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod. Pathol. 2010, 23:531-538.
56. Dempke W., Voigt W., Grothey A., Hill B.T., Schmoll H.J. Cisplatin resistance and oncogenes - a review. Anticancer Drugs 2000, 11:225-236.
57. Takatori H., Natsugoe S., Okumura H., Matsumoto M., Ishigami S., Owaki T., Aikou T. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol. Rep. 2005, 13:697-701.
58. Fumoto S., Shimokuni T., Tanimoto K., Hiyama K., Otani K., Ohtaki M., Hihara J., Yoshida K., Hiyama E., Noguchi T., Nishiyama M. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int. J. Oncol. 2008, 32:413-423.
59. Chen C.Y., Fang H.Y., Chiou S.H., Yi S.E., Huang C.Y., Chiang S.F., Chang H.W., Lin T.Y., Chiang I.P., Chow K.C. Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci. 2011, 102(8):1582-1589. 10.1111/j.1349-7006.2011.01975.x.
60. Liu P., Khurana A., Rattan R., He X., Kalloger S., Dowdy S., Gilks B., Shridhar V. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res. 2009, 69:4843-4850.
61. Sumi K., Tago K., Kasahara T., Funakoshi-Tago M. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett. 2011, 585:1884-1890.
62. Zaffaroni N., Daidone M.G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat. 2002, 5:65-72.
63. Nakatani K., Wada T., Nakamura M., Uzawa K., Tanzawa H., Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2005, 131:445-452.
64. Guo W., Zhang Y., Chen T., Wang Y., Xue J., Zhang Y., Xiao W., Mo X., Lu Y. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J. Cancer Res. Clin. Oncol. 2011, 137:65-72.
65. Helleman J., Jansen M.P., Span P.N., van Staveren I.L., Massuger L.F., Meijer-van Gelder M.E., Sweep F.C., Ewing P.C., van der Burg M.E., Stoter G., Nooter K., Berns E.M. Molecular profiling of platinum resistant ovarian cancer. Int. J. Cancer 2006, 118:1963-1971.
66. Schmidmaier R., Baumann P. Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr. Med. Chem. 2008, 15:978-990.
67. Klominek J., Sumitran K.S., Hauzenberger D. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int. J. Cancer 1997, 72:1034-1044.
68. Fukuoka K., Tanaka F., Tsujimura T., Hashimoto-Tamaoki T., Hasegawa S., Nakano T. Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma. Nippon Eiseigaku Zasshi 2011, 66:553-557.
69. Scherpereel A., Grigoriu B., Conti M., Gey T., Gregoire M., Copin M.C., Devos P., Chahine B., Porte H., Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173:1155-1160.
70. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
71. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:136-140.
72. Zhang D., Kobayashi T., Kojima T., Kanenishi K., Hagiwara Y., Abe M., Okura H., Hamano Y., Sun G., Maeda M., Jishage K., Noda T., Hino O. Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice. Cancer Sci. 2011, 102:720-727.
73. Li Q., Wang W., Yamada T., Matsumoto K., Sakai K., Bando Y., Uehara H., Nishioka Y., Sone S., Iwakiri S., Itoi K., Utsugi T., Yasumoto K., Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am. J. Pathol. 2011, 179:1483-1493.
74. Ricci A., Mariotta S., Pompili E., Mancini R., Bronzetti E., De V.C., Pisani L., Cherubini E., Bruno P., Gencarelli G., Giovagnoli M.R., Terzano C., Ciliberto G., Giarnieri E., Fumagalli L. Neurotrophin system activation in pleural effusions. Growth Factors 2010, 28:221-231.
75. Singhal S., Wiewrodt R., Malden L.D., Amin K.M., Matzie K., Friedberg J., Kucharczuk J.C., Litzky L.A., Johnson S.W., Kaiser L.R., Albelda S.M. Gene expression profiling of malignant mesothelioma. Clin. Cancer Res. 2003, 9:3080-3097.
76. Mohr S., Keith G., Galateau-Salle F., Icard P., Rihn B.H. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim. Biophys. Acta 2004, 1688:43-60.
77. Roe O.D., Anderssen E., Helge E., Pettersen C.H., Olsen K.S., Sandeck H., Haaverstad R., Lundgren S., Larsson E. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One 2009, 4:e6554.
78. Roe O.D., Anderssen E., Sandeck H., Christensen T., Larsson E., Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2010, 67:57-68.